Aminexil vs minoxidil: what the science really says in 2026

Aminexil vs Minoxidil: What the Science Really Says in 2026

Walk into almost any European pharmacy and you will find two products sitting side by side on the hair loss shelf: an Aminexil lotion and a Minoxidil solution or foam. They look remarkably alike, promise very similar outcomes, and target the exact same worried customer. Yet, from a scientific and regulatory perspective, these two options belong to completely different worlds. One is classified purely as a cosmetic ingredient, while the other is an authorised medicinal treatment.

Two Molecules, Two Different Problems

Before comparing efficacy (how well they actually work), it helps to understand that Aminexil and Minoxidil were designed to solve completely different biological problems inside the hair follicle, which is the tiny pocket in the skin that produces each strand of hair.

Minoxidil: a vasodilator turned hair growth stimulator

Minoxidil was originally developed in the 1970s as an oral medication for severe hypertension, which is high blood pressure. Doctors quickly noticed that patients grew unexpected body hair, leading to the development of topical formulations (liquids or foams applied directly to the scalp) approved in 1988. Minoxidil is a prodrug, meaning it is an inactive molecule that must first be converted inside the hair follicle into its active form, minoxidil sulfate, by a natural scalp enzyme (a specialized protein helper) called sulfotransferase or SULT1A1. Once activated, it opens cellular pathways known as ATP-sensitive potassium channels, which act like microscopic gates. This process shortens the telogen phase (the resting stage when hair prepares to shed), pushes follicles rapidly into the anagen phase (the active growth stage), prolongs this growth cycle, and upregulates VEGF, a signal protein that encourages blood vessel growth to nourish the roots. Crucially, minoxidil does not affect the androgen pathway, meaning it has no effect on the male hormones responsible for genetic hair loss.

Aminexil: an anti-fibrosis strategy

Aminexil, also known chemically as diaminopyrimidine oxide or kopexil, was developed by L'Oréal. Despite widespread internet claims, it is not a direct chemical derivative of minoxidil. Its proposed mechanism of action targets perifollicular fibrosis, which is the stiffening and hardening of collagen tissue around the hair root that can restrict healthy growth. Aminexil is believed to inhibit lysyl hydroxylase, an enzyme that helps build this rigid collagen barrier, thereby softening the sheath surrounding the follicles. However, the European Union Scientific Committee has stated that it remains unknown whether 2,4-DPO, the scientific name for Aminexil, exerts any real pharmacological activity (actual therapeutic drug effect) at standard cosmetic concentrations.

The Regulatory Reality: Cosmetic vs. Medicine

Under EU Regulation (EC) No 1223/2009, a cosmetic product is defined very narrowly. Any product that claims to treat or prevent a medical disease is classified as a medicinal product, requiring strict governmental authorisation. Aminexil sits firmly on the cosmetic side of this line, meaning it is restricted to a maximum concentration of 1.5% in commercial hair products. In contrast, topical minoxidil holds a formal marketing authorisation as an approved medicinal product. This status means it has successfully passed rigorous, randomised, placebo-controlled trials (scientific gold-standard studies comparing the drug to a dummy substance), has a highly defined safety profile, and undergoes continuous pharmacovigilance, which is the official monitoring of side effects in the general population. Simply being sold on a pharmacy shelf does not make a cosmetic product a medicine.

What the Clinical Evidence Really Shows

Minoxidil: robust randomised controlled trials

A major 48-week clinical trial conducted by Olsen in 393 men showed that a 5% topical minoxidil solution produced approximately 45% more non-vellus hair, which are the thick, fully mature, and visible hairs rather than fine peach fuzz, compared to the weaker 2% version. A parallel trial involving 381 women confirmed the clinical superiority of the 5% concentration. Consequently, the European S3 evidence-based medical guidelines rate topical minoxidil at Evidence Level 1, which represents the highest possible standard of scientific proof. Real-world response rates generally range from 60% to 85%, although only about one-third of users experience a highly visible, cosmetically significant regrowth after a full year. This variation exists because individual response depends heavily on the natural activity level of the SULT1A1 enzyme in the scalp, which converts the compound into its active form.

Aminexil: observational data, no confirmatory RCT

The strongest human evidence currently available for Aminexil comes from the observational Aminexil Clinical 5 study of 527 adults, which reported a dermatologist-rated improvement in 87.1% of participants. However, this study was open-label, meaning both the researchers and the participants knew what was being administered, and it featured no comparison group receiving a placebo. Furthermore, the clinical endpoint, or primary measured goal, was simply a reduction in hair shedding rather than confirmed new hair regrowth. A head-to-head animal study revealed that Aminexil showed the weakest hair growth effect among all the products tested, whereas a 2% minoxidil solution significantly stimulated active regrowth. Although a 2024 preclinical laboratory mouse study suggested a different outcome, animal models cannot substitute for a proper double-blind human RCT (a randomised controlled trial where neither patient nor doctor knows who is getting the active ingredient or a dummy treatment to eliminate bias), which does not yet exist for Aminexil.

Head-to-Head Comparison

Safety Profile

Minoxidil: effective but with real side effects

The most common adverse events, which are localized side effects, are typically mild and scalp-focused: itching (occurring in 7% to 13% of users), redness, dryness, and flaking. Propylene glycol, an inactive liquid carrier used in the liquid solution but not in the foam formulation, is the primary sensitiser, meaning the main ingredient responsible for triggering scalp irritation and allergic reactions. Hypertrichosis, which is the growth of unwanted, fine hair on areas other than the scalp like the face, affects roughly 3% to 7% of women in controlled clinical trials and up to 21% in real-world observational studies. Additionally, almost every new user experiences a temporary initial shedding phase during weeks 4 to 8 of treatment, which is a normal process where older hairs are pushed out to make room for stronger new ones.

Aminexil: exceptionally well tolerated

Aminexil stands out for having excellent scalp tolerability, with zero reported cases of hypertrichosis (unwanted facial hair growth), no initial shedding phase, and minimal risk of contact dermatitis, which is an itchy, allergic skin rash. Overall tolerance was rated as good to very good in 98.6% of study participants. However, local physical comfort and cosmetic ease of use should never be confused with actual therapeutic efficacy, which is the proven ability of a treatment to successfully regrow hair.

How to Choose: A Clinical Decision Framework

Confirmed androgenetic alopecia

Topical minoxidil, applied at 5% for men and 2% or 5% for women, remains the absolute reference first-line topical treatment (the primary, gold-standard therapy recommended first by medical professionals) in 2026. If scalp irritation is a primary concern for you, choosing a propylene-glycol-free foam formulation can prevent itchy reactions. If you find that you cannot tolerate topical applications applied directly to the skin, you may want to discuss low-dose oral minoxidil, a systemic pill taken in small doses of 0.25 to 2.5 mg daily, with your dermatologist.

Diffuse telogen effluvium

Aminexil may reasonably be used as a supportive adjunct, which is a secondary helper treatment, to help reduce excessive shedding while the underlying lifestyle or medical trigger is being corrected. However, you should not expect this cosmetic compound to trigger the active regrowth of miniaturised hairs, which are the progressively thinning and shrinking hair strands characteristic of genetic balding.

Combining both

Combining both treatments is theoretically attractive because the two molecules act on entirely complementary biological pathways in the scalp. However, to date, no large, peer-reviewed RCT (a high-quality study thoroughly checked by independent medical experts) has successfully demonstrated that adding Aminexil to your routine improves actual hair density outcomes over Minoxidil monotherapy, which means using Minoxidil completely on its own.

What About Oral Minoxidil in 2026?

The most significant recent shift in hair loss management is the rapid rise of low-dose oral minoxidil, which is prescribed off-label (meaning physicians use this approved medication for hair loss even though it was originally approved for high blood pressure) at low daily doses of 0.25 to 2.5 mg. This pill option offers comparable efficacy to the topical version without causing any localized scalp irritation, but it comes with important cardiovascular considerations, such as potential impacts on blood pressure and heart rate, meaning it must always be carefully evaluated and prescribed by a qualified physician.

Conclusion

The scientific comparison between aminexil and minoxidil is simply not a level playing field. Minoxidil is an officially authorised medicine backed by decades of robust, randomised clinical trials. Aminexil is a well-tolerated cosmetic ingredient with promising theoretical mechanisms but no confirmatory human clinical trials to prove its hair-growing power. If your primary goal is to reduce general shedding gently and supportively, Aminexil is a reasonable cosmetic option. However, if your goal is to slow down and actively reverse androgenetic alopecia, which is the medical term for hereditary pattern hair loss, Minoxidil remains the gold-standard reference. At Hairdex, we believe that patients deserve a completely transparent, evidence-based framework to make informed decisions about their hair health.

Frequently Asked Questions

Can aminexil and minoxidil be used together?

Yes, you can use them together because there is no known chemical incompatibility between the two, and their biological mechanisms are complementary. However, it is important to note that no large, randomized clinical trial has yet proven that adding Aminexil to a Minoxidil routine produces significantly better regrowth outcomes than using Minoxidil alone.

Which is better for hair fall?

For androgenetic alopecia, which is genetic hair thinning, Minoxidil has significantly stronger clinical evidence and stands as the primary reference treatment. For mild, temporary shedding, Aminexil serves as a highly tolerable, non-irritating cosmetic option to help manage hair fall.

Can aminexil regrow lost hair?

Current scientific evidence does not support this claim. While observational studies show a general reduction in hair shedding, no randomized controlled trials have ever demonstrated that Aminexil can stimulate significant new hair regrowth in humans.

Does aminexil block DHT?

No. Aminexil does not act on the androgen pathway, meaning it does not interfere with male hormones. Neither does Minoxidil. For actual DHT blockade, which means stopping dihydrotestosterone, the key hormone responsible for shrinking hair follicles, prescription medical treatments like finasteride or dutasteride are required.

What happens if you stop minoxidil?

Any newly gained hair grown because of the treatment will progressively shed and fall out over a period of 12 to 24 weeks, ultimately returning your scalp to its original, pre-treatment state.

References

[1] Jalilzadeh S, Hamishehkar H, Monajjemzadeh F. Kopexil vs minoxidil: In vivo comparative study on hair growth, hair growth promoting factors and toxicity. Bioimpacts. 2024. Read the source

[2] Ashique S, Sandhu NK, Haque SN, Koley K. A Systemic Review on Topical Marketed Formulations, Natural Products, and Oral Supplements to Prevent Androgenic Alopecia: A Review. Nat Prod Bioprospect. 2020. Read the source

[3] Orasan MS, Bolfa P, Coneac A, Muresan A, Mihu C. Topical Products for Human Hair Regeneration: A Comparative Study on an Animal Model. Ann Dermatol. 2016. Read the source

[4] Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019. Read the source

[5] Shadi Z. Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatol Ther (Heidelb). 2023. Read the source

[6] SCCNFP. Opinion concerning Diaminopyrimidine oxide (2,4-DPO) adopted by the SCCNFP during the 12th plenary meeting of 3 May 2000. European Commission Scientific Committee on Cosmetic Products. 2000. Read the source

[7] Patel P, Nessel TA, Kumar D. Minoxidil. StatPearls. 2023. Read the source

[8] Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004. Read the source

[9] Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004. Read the source

[10] Reygagne P, Mandel VD, Delva C, Havlíčková M, Padlewska K, Khalil R, et al. Subjects with mild alopecia benefit from aminexil clinical 5: results of a large international observational study. 29th EADV Congress. 2020. Read the source

[11] Amiri R, Mohammadi S, Azizi S, Pardakhty A, Khalili M, Aflatoonian M. Evaluation of efficacy and safety profile of niosomal kopexil 1% lotion compared to niosomal minoxidil 2% lotion in male-pattern alopecia. Iranian Journal of Dermatology. 2023. Read the source

[12] Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. Frontiers in Pharmacology. 2025. Read the source

[13] Hussein RS, Bin Dayel S, Abahussein O, El‐Sherbiny AA. Applications and efficacy of minoxidil in dermatology. Skin Health Dis. 2024. Read the source